Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial

Am J Cardiol. 2001 Jul 15;88(2):192-5, A6-7. doi: 10.1016/s0002-9149(01)01622-8.

Abstract

The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) is a large, randomized, placebo-controlled, regimen-finding trial of intra-arterial recombinant fibroblast growth factor-2 in patients with intermittent claudication. This report describes the major design considerations and end points in TRAFFIC.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Double-Blind Method
  • Fibroblast Growth Factor 2 / therapeutic use*
  • Humans
  • Intermittent Claudication / drug therapy*
  • Neovascularization, Physiologic / drug effects*
  • Recombinant Proteins / therapeutic use
  • Research Design

Substances

  • Recombinant Proteins
  • Fibroblast Growth Factor 2